OncoCiDia: A Novel Depersonalized Combination of Targeted Chemo- and Radio-Theragnostics for the Management of Solid Malignancies

International Conference on Nuclear Medicine & Radiation Therapy

July 14-15, 2016 Cologne, Germany

Yicheng Ni

KU Leuven, Belgium

Posters & Accepted Abstracts: J Nucl Med Radiat Ther

Abstract :

Imaging and contrast media research has enabled discovery of small molecular necrosis-avid compounds (NACs) for the diagnosis of myocardial infarction and therapeutic assessment of tumor ablation with MRI, nuclear scintigraphy and optical imaging1,2. The in vivo affinity of NACs to necrosis appears orders of magnitude higher than antigen-antibody, ligand-receptor and biotinavidin interactions in vivo. Based on a soil-to-seeds hypothesis3, this stroma targetability is extended from diagnostic to theragnostic utilities by combined use of vascular disrupting agents (VDAs) such as CA4P to formulate a novel pan-anticancer approach, namely a small-molecular sequential dual targeting theragnostic strategy3. The dual targeting properties and conjugated iodine-131 that emits both beta and gamma radiations provide solid cancers (Onco) with both tumoricidal (Ci) and imaging diagnostic (Dia) effects, hence an acronym OncoCiDia3. Instead of directly attacking multimutant and refractory cancer cells (seeds) as in other cancer therapies, OncoCiDia selectively destroys and radioactively sterilizes the tumor microenvironment (soil)4. Multicenter preclinical investigations on the efficacy, safety, formulations and dosimetry suggest that this novel and unconventional anticancer strategy may present a relatively simple, workable, affordable and generic solution for diverse cancer problems, and deserve further exploitation.

Biography :

Email: Yicheng.Ni@med.kuleuven.be